Insights on Clinical Trial Enrollment | 2022 Downloadable Report
Insights on Clinical Trial Enrollment: Where We Are as We Head Into 2022
The last two years have brought tremendous change and rapid innovation to the life sciences industry. Yet, patient enrollment persists as a critical challenge for sponsors and CROs.
Currently, 80% of trials do not enroll within target enrollment timeframes and 55% of terminated trials cite low patient accrual as the main reason.
As the pandemic continues to fluctuate, we look back at 2021 to assess the continued impact of the pandemic on clinical trial enrollment to help the industry navigate the dynamic landscape as we enter 2022. This report highlights granular trial enrollment insights across therapeutic areas (oncology, immunomodulation, central nervous system (CNS), and cardiovascular) and geographic regions (North America, Europe, Asia).